With Restasis in its crosshairs, Mylan adds a Botox biosim with Revance; Vertex starts second PhIII triple combo CF study
→ With Mylan $MYL already moving in for the kill with a generic version of Allergan’s Restasis, the big generics company has set up a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
